Navigation Links
Biovista Inc. Announces Drug Repositioning Collaboration with Astellas Pharma
Date:12/2/2015

CHARLOTTESVILLE, Virginia, December 2, 2015 /PRNewswire/ --

Biovista announced today that it has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista's Clinical Outcome Search Space (COSS) technology.

"We look forward to working with the Drug Repurposing and Application Management at Astellas to compliment their work," said Dr. Aris Persidis, President of Biovista. "Our very large scale systematic drug repositioning technology (the "Clinical Outcome Search Space - COSS(tm) offers the advantages of speed, comprehensiveness and depth of clinical outcome exploration, which we hope will help patients in need benefit even more from Astellas drugs," he added.

About Astellas:

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at http://www.astellas.com/en .

About Biovista:

Biovista is a privately held biotechnology company that finds novel uses for existing drugs, and profiles their side effects using their mechanism of action. Biovista is developing its own drug pipeline in multiple indications and is collaborating with the FDA on the prediction of adverse events, as well as with biopharmaceutical companies on indication expansion and de-risking of their portfolios (http://www.biovista.com ).

For further information please contact:

Dr. Aris Persidis, E: arisp@biovista.com


'/>"/>
SOURCE Biovista Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Biovista and the CFIDS Association of America Achieve Drug Repositioning Milestone with Pre-IND Meeting
2. Neue Publikation von Biovista Inc.: EMR-Daten bestätigen die Vorhersage von Big Data Analytics, dass Hypothyreose einen Risikofaktor für das Neuaufteten von Diabetes Mellitus darstellt
3. New Biovista Inc. Publication: EMR Data Confirm Big Data Analytics Prediction That Hypothyroidism is a Risk Factor for New-onset Diabetes Mellitus
4. Biovista Inc. gibt Zusammenarbeit mit Astellas Pharma zwecks Umpositionierung von Arzneimitteln bekannt
5. Pharmagen Announces First Quarter 2013 Results
6. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
7. Vasomedical Announces Financial Results for the First Quarter of 2013
8. TSI Announces 2013 Respiratory Protection Roadshow Training Dates and Locations
9. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
10. Active Life Announces $500K Follow On Series A Investment - Tech Coast Angels Re-up
11. Pentec Health Announces Limited Voluntary Recall of Certain Compounded Prescription Therapies for Renal Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/11/2019)... ... November 11, 2019 , ... MAPS and ... implementation of joint projects for the benefit of biomedical professionals in the ... professionals to leverage their roles in the research, development, and commercialization activities ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... drug class and have a major impact in the oncology field. While ... need to be overcome. Among these, defining valuable and adapted combination protocols, ...
(Date:11/11/2019)... (PRWEB) , ... November 10, 2019 , ... ... rebranding alongside a redesign of its website , which features over 600 ... from the brand's 35+ year commitment to providing high-quality health and wellness products, ...
Breaking Medicine Technology:
(Date:11/11/2019)... ... 11, 2019 , ... As Americans celebrate Veterans Day and honor the brave ... remember that they also deserve recognition and compassionate care when dealing with an advanced ... is demonstrating its commitment to providing specialized care for Veterans who are facing ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... for improved foodborne illness prevention and urges increased adoption of compliance technology in ... series of vegetable products sold to select retailers in the United States and ...
(Date:11/9/2019)... ... 08, 2019 , ... Mount Sinai Medical-Legal Partnership (MSMLP), an organization formed to ... free special education law and advocacy assistance to families and patients in need. The ... the work of contributions of Blaine (“Fin”) Fogg, who was a member of the ...
(Date:11/7/2019)... ... 07, 2019 , ... , Entomol’s safe and effective, EPA-approved all-natural insect ... a 4 and a 7 hour formulations. , “Entomol helps people live healthier lives ... Virus and Encephalitis, without exposing them to the harmful chemicals found in other repellents,” ...
(Date:11/6/2019)... ... November 06, 2019 , ... SPH Analytics , ... today that 94% of the health insurance plans receiving the highest 4.5- to ... plans, use SPH solutions according to reports recently released by the ...
Breaking Medicine News(10 mins):